We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cambrex has received a warning letter related to a March FDA inspection of its manufacturing facility in Milan, which makes active pharmaceutical ingredients (APIs) for generic drugs.